ITGAM and leukemia: To evaluate the microenvironment along with changes in leukemia burden, FC analyses of BM show that overall proportions of murine CD11b+ and F4/80+ monocytic cells or MΦ do not change significantly upon treatments (Fig. 5Ci–ii), but the proportion of murine protumoral M2-like CD206+ MΦ [38] decreases significantly in double-treated mice (Fig. 5Ciii).